Tratamento do líquen plano oral recalcitrante com tacrolimo 0,1 %
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
The oral lichen planus (OLP) has been considered a chronic-course auto
immune inflammatory disease and its presence may be related
to increased emotional stress. The clinical relevance of OLP is the possibility, in
developing a squamous cell carcinoma which its etiology is still obscure and
unknown. The aim of the present study is to treat OLP lesions that were recalcitrant
to conventional treatment with corticosteroids, using topical Tacrolimus 0.1% (Protopic®), applied twice a day, for a period of eight weeks. Fifteen patients were
selected who had filled out a history form and a visual scale for pain before and after
treatment. All patients were submitted to an initial biopsy for the diagnosis of the
disease and another one at the end to evaluate the effect of medication on the
infiltrate. A weekly control was carried out, observing the clinical aspects, painful
symptoms and the occurrence of side effects which, where present, were mild and
transient. The results showed twelve patients (80%) with total or nearly total
remission of painful symptoms and lesions, two patients (13.33%) showed the
clearer lesions and only one patient (6.67%) did not obtain any change in clinical
symptoms and pain. Throught the analysis of the histopathological features
regression of OLP, if could be noticed a moderate or accented regression in twelve
patients (80%) and an absent or mild regression in three patients (20%). Based on the our results, it was possible to conclude that the Tacrolimus 0.1% (Protopic®)is a
safe and effective medication that improves the clinical aspect of the injury, reduces
the painful symptoms and reduces the histopathological features of the OLP.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
